Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Update

Compass Therapeutics, Inc. (NASDAQ:CMPX) was the target of a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 2,750,000 shares, a decrease of 13.8% from the January 15th total of 3,190,000 shares. Currently, 3.3% of the shares of the stock are sold short. Based on an average trading volume of 1,280,000 shares, the short-interest ratio is presently 2.1 days.

Analyst Ratings Changes

CMPX has been the subject of a number of analyst reports. Jefferies Financial Group upped their price objective on shares of Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, February 10th. D. Boral Capital reiterated a “buy” rating and issued a $32.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Leerink Partnrs downgraded shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Finally, Leerink Partners cut shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $5.00 to $4.00 in a research note on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $11.17.

Institutional Trading of Compass Therapeutics

Several large investors have recently bought and sold shares of the business. MPM Bioimpact LLC grew its stake in Compass Therapeutics by 51.9% during the 4th quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company’s stock valued at $12,423,000 after acquiring an additional 2,926,002 shares in the last quarter. Enavate Sciences GP LLC purchased a new stake in Compass Therapeutics during the 4th quarter valued at about $11,293,000. Tang Capital Management LLC grew its stake in Compass Therapeutics by 225.4% during the 4th quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company’s stock valued at $8,555,000 after acquiring an additional 4,087,005 shares in the last quarter. Rock Springs Capital Management LP grew its stake in Compass Therapeutics by 2.7% during the 4th quarter. Rock Springs Capital Management LP now owns 5,779,575 shares of the company’s stock valued at $8,380,000 after acquiring an additional 150,336 shares in the last quarter. Finally, Blue Owl Capital Holdings LP grew its stake in Compass Therapeutics by 2.6% during the 4th quarter. Blue Owl Capital Holdings LP now owns 2,954,712 shares of the company’s stock valued at $4,284,000 after acquiring an additional 75,000 shares in the last quarter. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Price Performance

CMPX stock opened at $3.38 on Tuesday. The firm has a 50-day simple moving average of $2.31 and a 200-day simple moving average of $1.83. Compass Therapeutics has a 52 week low of $0.76 and a 52 week high of $4.08.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.